메뉴 건너뛰기




Volumn 49, Issue 7, 2014, Pages 913-920

Reduced toxicity, myeloablative conditioning with BU, fludarabine, alemtuzumab and SCT from sibling donors in children with sickle cell disease

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; BUSULFAN; CD56 ANTIGEN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; FLUDARABINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTAMIDINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TACROLIMUS; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; VIDARABINE;

EID: 84903882984     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2014.84     Document Type: Article
Times cited : (89)

References (37)
  • 1
    • 10744233940 scopus 로고    scopus 로고
    • Pulmonary hypertension as a risk factor for death in patients with sickle cell disease
    • Gladwin MT, Sachdev V, Jison ML, Shizukuda Y, Plehn JF, Minter K et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004; 350: 886-895.
    • (2004) N Engl J Med , vol.350 , pp. 886-895
    • Gladwin, M.T.1    Sachdev, V.2    Jison, M.L.3    Shizukuda, Y.4    Plehn, J.F.5    Minter, K.6
  • 2
    • 33644775612 scopus 로고    scopus 로고
    • Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease
    • Kato GJ, McGowan V, Machado RF, Little JA, Jt Taylor, Morris CR et al. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood 2006; 107: 2279-2285.
    • (2006) Blood , vol.107 , pp. 2279-2285
    • Kato, G.J.1    McGowan, V.2    Machado, R.F.3    Little, J.A.4    Taylor, J.T.5    Morris, C.R.6
  • 5
    • 34948830175 scopus 로고    scopus 로고
    • Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease
    • Bernaudin F, Socie G, Kuentz M, Chevret S, Duval M, Bertrand Y et al. Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. Blood 2007; 110: 2749-2756.
    • (2007) Blood , vol.110 , pp. 2749-2756
    • Bernaudin, F.1    Socie, G.2    Kuentz, M.3    Chevret, S.4    Duval, M.5    Bertrand, Y.6
  • 7
    • 0031870487 scopus 로고    scopus 로고
    • Haematopoietic stem cell transplantation for sickle cell anaemia: The first 50 patients transplanted in Belgium
    • Vermylen C, Cornu G, Ferster A, Brichard B, Ninane J, Ferrant et al. Haematopoietic stem cell transplantation for sickle cell anaemia: the first 50 patients transplanted in Belgium. Bone Marrow Transplant 1998; 22: 1-6.
    • (1998) Bone Marrow Transplant , vol.22 , pp. 1-6
    • Vermylen, C.1    Cornu, G.2    Ferster, A.3    Brichard, B.4    Ninane, J.5    Ferrant6
  • 9
    • 84886897873 scopus 로고    scopus 로고
    • Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling
    • Locatelli F, Kabbara N, Ruggeri A, Ghavamzadeh A, Roberts I, Li CK et al. Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling. Blood 2013; 122: 1072-1078.
    • (2013) Blood , vol.122 , pp. 1072-1078
    • Locatelli, F.1    Kabbara, N.2    Ruggeri, A.3    Ghavamzadeh, A.4    Roberts, I.5    Li, C.K.6
  • 10
    • 38849161460 scopus 로고    scopus 로고
    • Hematopoietic cell transplantation for thalassemia and sickle cell disease: Past, present and future
    • Bhatia M, Walters MC. Hematopoietic cell transplantation for thalassemia and sickle cell disease: past, present and future. Bone Marrow Transplant 2008; 41: 109-117.
    • (2008) Bone Marrow Transplant , vol.41 , pp. 109-117
    • Bhatia, M.1    Walters, M.C.2
  • 13
    • 19944392296 scopus 로고    scopus 로고
    • Reduced-intensity allogeneic stem cell transplantation in adults and children with malignant and nonmalignant diseases: End of the beginning and future challenges
    • Satwani P, Harrison L, Morris E, Del Toro G, Cairo MS. Reduced-intensity allogeneic stem cell transplantation in adults and children with malignant and nonmalignant diseases: end of the beginning and future challenges. Biol Blood Marrow Transplant 2005; 11: 403-422.
    • (2005) Biol Blood Marrow Transplant , vol.11 , pp. 403-422
    • Satwani, P.1    Harrison, L.2    Morris, E.3    Del Toro, G.4    Cairo, M.S.5
  • 14
    • 36849036789 scopus 로고    scopus 로고
    • Reduced intensity and non-myeloablative allogeneic stem cell transplantation in children and adolescents with malignant and non-malignant diseases
    • Satwani P, Morris E, BradLey MB, Bhatia M, van de Ven C, Cairo MS. Reduced intensity and non-myeloablative allogeneic stem cell transplantation in children and adolescents with malignant and non-malignant diseases. Pediatr Blood Cancer 2008; 50: 1-8.
    • (2008) Pediatr Blood Cancer , vol.50 , pp. 1-8
    • Satwani, P.1    Morris, E.2    Bradley, M.B.3    Bhatia, M.4    Van De Ven, C.5    Cairo, M.S.6
  • 15
    • 79958089426 scopus 로고    scopus 로고
    • A pilot study of reduced toxicity conditioning with BU, fludarabine and alemtuzumab before the allogeneic hematopoietic SCT in children and adolescents
    • Styczynski J, Tallamy B, Waxman I, van de Ven C, Milone MC, Shaw LM et al. A pilot study of reduced toxicity conditioning with BU, fludarabine and alemtuzumab before the allogeneic hematopoietic SCT in children and adolescents. Bone Marrow Transplant 2011; 46: 790-799.
    • (2011) Bone Marrow Transplant , vol.46 , pp. 790-799
    • Styczynski, J.1    Tallamy, B.2    Waxman, I.3    Van De Ven, C.4    Milone, M.C.5    Shaw, L.M.6
  • 17
    • 80053560138 scopus 로고    scopus 로고
    • A comparison of immune reconstitution and graft-versus-host disease following myeloablative conditioning versus reduced toxicity conditioning and umbilical cord blood transplantation in paediatric recipients
    • Geyer MB, Jacobson JS, Freedman J, George D, Moore V, van de Ven C et al. A comparison of immune reconstitution and graft-versus-host disease following myeloablative conditioning versus reduced toxicity conditioning and umbilical cord blood transplantation in paediatric recipients. Br J Haematol 2011; 155: 218-234.
    • (2011) Br J Haematol , vol.155 , pp. 218-234
    • Geyer, M.B.1    Jacobson, J.S.2    Freedman, J.3    George, D.4    Moore, V.5    Van De Ven, C.6
  • 19
    • 11144354112 scopus 로고    scopus 로고
    • A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients
    • Osunkwo I, Bessmertny O, Harrison L, Cheung YK, Van de Ven C, del Toro G et al. A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients. Biol Blood Marrow Transplant 2004; 10: 246-258.
    • (2004) Biol Blood Marrow Transplant , vol.10 , pp. 246-258
    • Osunkwo, I.1    Bessmertny, O.2    Harrison, L.3    Cheung, Y.K.4    Van De Ven, C.5    Del Toro, G.6
  • 20
    • 75749085170 scopus 로고    scopus 로고
    • An age-dependent pharmacokinetic study of intravenous and oral mycophenolate mofetil in combination with tacrolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipients
    • Bhatia M, Militano O, Jin Z, Figurski M, Shaw L, Moore V et al. An age-dependent pharmacokinetic study of intravenous and oral mycophenolate mofetil in combination with tacrolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipients. Biol Blood Marrow Transplant 2010; 16: 333-343.
    • (2010) Biol Blood Marrow Transplant , vol.16 , pp. 333-343
    • Bhatia, M.1    Militano, O.2    Jin, Z.3    Figurski, M.4    Shaw, L.5    Moore, V.6
  • 21
    • 0016187133 scopus 로고
    • Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors
    • Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-304.
    • (1974) Transplantation , vol.18 , pp. 295-304
    • Glucksberg, H.1    Storb, R.2    Fefer, A.3    Buckner, C.D.4    Neiman, P.E.5    Clift, R.A.6
  • 22
    • 65549157537 scopus 로고    scopus 로고
    • Sequential administration of sargramostim and filgrastim in pediatric allogeneic stem cell transplantation recipients undergoing myeloablative conditioning
    • Waxman IM, Militano O, Baldinger L, Roman E, Qualter E, Morris E et al. Sequential administration of sargramostim and filgrastim in pediatric allogeneic stem cell transplantation recipients undergoing myeloablative conditioning. Pediatr Transplant 2009; 13: 464-474.
    • (2009) Pediatr Transplant , vol.13 , pp. 464-474
    • Waxman, I.M.1    Militano, O.2    Baldinger, L.3    Roman, E.4    Qualter, E.5    Morris, E.6
  • 23
    • 37549006408 scopus 로고    scopus 로고
    • Liposomal amphotericin B prophylaxis of invasive mold infections in children post allogeneic stem cell transplantation
    • Roman E, Osunkwo I, Militano O, Cooney E, van de Ven C, Cairo MS. Liposomal amphotericin B prophylaxis of invasive mold infections in children post allogeneic stem cell transplantation. Pediatr Blood Cancer 2008; 50: 325-330.
    • (2008) Pediatr Blood Cancer , vol.50 , pp. 325-330
    • Roman, E.1    Osunkwo, I.2    Militano, O.3    Cooney, E.4    Van De Ven, C.5    Cairo, M.S.6
  • 24
    • 34547775136 scopus 로고    scopus 로고
    • A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients
    • Shereck EB, Cooney E, van de Ven C, Della-Lotta P, Cairo MS. A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients. Pediatr Blood Cancer 2007; 49: 306-312.
    • (2007) Pediatr Blood Cancer , vol.49 , pp. 306-312
    • Shereck, E.B.1    Cooney, E.2    Van De Ven, C.3    Della-Lotta, P.4    Cairo, M.S.5
  • 25
    • 63949085142 scopus 로고    scopus 로고
    • Feasibility study of preemptive withdrawal of immunosuppression based on chimerism testing in children undergoing myeloablative allogeneic transplantation for hematologic malignancies
    • Horn B, Soni S, Khan S, Petrovic A, Breslin N, Cowan M et al. Feasibility study of preemptive withdrawal of immunosuppression based on chimerism testing in children undergoing myeloablative allogeneic transplantation for hematologic malignancies. Bone Marrow Transplant 2009; 43: 469-476.
    • (2009) Bone Marrow Transplant , vol.43 , pp. 469-476
    • Horn, B.1    Soni, S.2    Khan, S.3    Petrovic, A.4    Breslin, N.5    Cowan, M.6
  • 26
    • 70350572382 scopus 로고    scopus 로고
    • Incidence of Viral and fungal infections following busulfan-based reducedintensity versus myeloablative conditioning in pediatric allogeneic stem cell transplantation recipients
    • Satwani P, Baldinger L, Freedman J, Jacobson JS, Guerra J, van de Ven C et al. Incidence of Viral and fungal infections following busulfan-based reducedintensity versus myeloablative conditioning in pediatric allogeneic stem cell transplantation recipients. Biol Blood Marrow Transplant 2009; 15: 1587-1595.
    • (2009) Biol Blood Marrow Transplant , vol.15 , pp. 1587-1595
    • Satwani, P.1    Baldinger, L.2    Freedman, J.3    Jacobson, J.S.4    Guerra, J.5    Van De Ven, C.6
  • 27
    • 84862908566 scopus 로고    scopus 로고
    • Risk factors for acute GVHDand survival after hematopoietic cell transplantation
    • Jagasia M, Arora M, Flowers ME, Chao NJ, McCarthy PL, Cutler CS et al. Risk factors for acute GVHDand survival after hematopoietic cell transplantation. Blood 2012; 119: 296-307.
    • (2012) Blood , vol.119 , pp. 296-307
    • Jagasia, M.1    Arora, M.2    Flowers, M.E.3    Chao, N.J.4    McCarthy, P.L.5    Cutler, C.S.6
  • 28
    • 84873423706 scopus 로고    scopus 로고
    • Concise review: Acute graft-versus-host disease: Immunobiology, prevention, and treatment
    • Sung AD, Chao NJ. Concise review: acute graft-versus-host disease: immunobiology, prevention, and treatment. Stem Cells Transl Med 2013; 2: 25-32.
    • (2013) Stem Cells Transl Med , vol.2 , pp. 25-32
    • Sung, A.D.1    Chao, N.J.2
  • 29
    • 53749086728 scopus 로고    scopus 로고
    • Stable long-term donor engraftment following reduced-intensity hematopoietic cell transplantation for sickle cell disease
    • Krishnamurti L, Kharbanda S, Biernacki MA, Zhang W, Baker KS, Wagner JE et al. Stable long-term donor engraftment following reduced-intensity hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant 2008; 14: 1270-1278.
    • (2008) Biol Blood Marrow Transplant , vol.14 , pp. 1270-1278
    • Krishnamurti, L.1    Kharbanda, S.2    Biernacki, M.A.3    Zhang, W.4    Baker, K.S.5    Wagner, J.E.6
  • 30
    • 34247858963 scopus 로고    scopus 로고
    • Matched-related donor transplantation for sickle cell disease: Report from the Center for International Blood and Transplant Research
    • Panepinto JA, Walters MC, Carreras J, Marsh J, Bredeson CN, Gale RP et al. Matched-related donor transplantation for sickle cell disease: report from the Center for International Blood and Transplant Research. Br J Haematol 2007; 137: 479-485.
    • (2007) Br J Haematol , vol.137 , pp. 479-485
    • Panepinto, J.A.1    Walters, M.C.2    Carreras, J.3    Marsh, J.4    Bredeson, C.N.5    Gale, R.P.6
  • 31
    • 84875514036 scopus 로고    scopus 로고
    • Transplantationrelated mortality, graft failure, and survival after reduced-toxicity conditioningand allogeneic hematopoietic stem cell transplantation in 100 consecutive pediatric recipients
    • Satwani P, Jin Z, Duffy D, Morris E, Bhatia M, Garvin JH et al. Transplantationrelated mortality, graft failure, and survival after reduced-toxicity conditioningand allogeneic hematopoietic stem cell transplantation in 100 consecutive pediatric recipients. Biol Blood Marrow Transplant 2013; 19: 552-561.
    • (2013) Biol Blood Marrow Transplant , vol.19 , pp. 552-561
    • Satwani, P.1    Jin, Z.2    Duffy, D.3    Morris, E.4    Bhatia, M.5    Garvin, J.H.6
  • 33
    • 0036220398 scopus 로고    scopus 로고
    • Risk of recurrent stroke in children with sickle cell disease receiving blood transfusion therapy for at least five years after initial stroke
    • Scothorn DJ, Price C, Schwartz D, Terrill C, Buchanan GR, Shurney W et al. Risk of recurrent stroke in children with sickle cell disease receiving blood transfusion therapy for at least five years after initial stroke. J Pediatr 2002; 140: 348-354.
    • (2002) J Pediatr , vol.140 , pp. 348-354
    • Scothorn, D.J.1    Price, C.2    Schwartz, D.3    Terrill, C.4    Buchanan, G.R.5    Shurney, W.6
  • 34
    • 77649200764 scopus 로고    scopus 로고
    • High incidence of severe cyclosporine neurotoxicity in children affected by haemoglobinopaties undergoing myeloablative haematopoietic stem cell transplantation: Early diagnosis and prompt intervention ameliorates neurological outcome
    • Noe A, Cappelli B, Biffi A, Chiesa R, Frugnoli I, Biral E et al. High incidence of severe cyclosporine neurotoxicity in children affected by haemoglobinopaties undergoing myeloablative haematopoietic stem cell transplantation: early diagnosis and prompt intervention ameliorates neurological outcome. Ital J Pediatr 2010; 36: 14.
    • (2010) Ital J Pediatr , vol.36 , pp. 14
    • Noe, A.1    Cappelli, B.2    Biffi, A.3    Chiesa, R.4    Frugnoli, I.5    Biral, E.6
  • 35
    • 0037669432 scopus 로고    scopus 로고
    • Tacrolimusassociated posterior reversible encephalopathy syndrome after allogeneic haematopoietic stem cell transplantation
    • Wong R, Beguelin GZ, de Lima M, Giralt SA, Hosing C, Ippoliti C et al. Tacrolimusassociated posterior reversible encephalopathy syndrome after allogeneic haematopoietic stem cell transplantation. Br J Haematol 2003; 122: 128-134.
    • (2003) Br J Haematol , vol.122 , pp. 128-134
    • Wong, R.1    Beguelin, G.Z.2    De Lima, M.3    Giralt, S.A.4    Hosing, C.5    Ippoliti, C.6
  • 36
    • 84870804411 scopus 로고    scopus 로고
    • Allogeneic cellular and autologous stem cell therapy for sickle cell disease: 'Whom, When And How'
    • Freed J, Talano J, Small T, Ricci A, Cairo MS. Allogeneic cellular and autologous stem cell therapy for sickle cell disease: 'whom, when and how'. Bone Marrow Transplant 2012; 47: 1489-1498.
    • (2012) Bone Marrow Transplant , vol.47 , pp. 1489-1498
    • Freed, J.1    Talano, J.2    Small, T.3    Ricci, A.4    Cairo, M.S.5
  • 37
    • 84880698186 scopus 로고    scopus 로고
    • Sickle cell disease: Time for a closer look at treatment options?
    • Sheth S, Licursi M, Bhatia M. Sickle cell disease: time for a closer look at treatment options? Br J Haematol 2013; 162: 455-464.
    • (2013) Br J Haematol , vol.162 , pp. 455-464
    • Sheth, S.1    Licursi, M.2    Bhatia, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.